<DOC>
	<DOC>NCT00958412</DOC>
	<brief_summary>This is an extension of the phase II, three-arm, parallel design, dose-ranging, placebo-controlled, randomized, double-blind, multicenter study in which placebo or one (1) of two (2) dose levels of Proellex® was administered once-daily for four (4) months.</brief_summary>
	<brief_title>Study Evaluating the Safety and Efficacy of Proellex® in the Treatment of Endometriosis-extension Study</brief_title>
	<detailed_description />
	<mesh_term>Endometriosis</mesh_term>
	<criteria>Only subjects treated in the ZPE201 study will be allowed to enter the extension study. Subjects who withdrew from ZPE201 due to lack of treatment efficacy will also be invited to participate. All other subjects</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>48 Years</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>Endometriosis</keyword>
	<keyword>Pelvic pain</keyword>
	<keyword>Oral progesterone blocker</keyword>
</DOC>